Clinical Trial Update: Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel and prednisone with or without cediranib in metastatic prostate cancer refractory to hormone therapy; study terminated with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Cediranib (Cediranib)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Stage IV Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-03-11